Corsera: Maraganore, Meanwell bring the disease interception model to CV risk

Rooted in the belief that some cases of cardiovascular disease can be forestalled by identifying risk at an early age, a start-up led by biotech veterans John Maraganore and Clive Meanwell is advancing both an AI-guided tool and a bifunctional therapy that are designed to lengthen patients’ health spans.

Newly launched Corsera Health Inc. is building on work by scientific co-founder Brian Ference showing a correlation between early reduction in two key risk factors and disease prevention. In a weekend presentation at the European Society of Cardiology (ESC) meeting of data from the NATURE-LEGACY study, Ference showed that reducing LDL-C and blood pressure earlier in life led to a far lower risk of major adverse cardiovascular events (MACE) after age 66...